This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

U.S. FDA Approves ThromboGenics' JETREA® (Ocriplasmin) For The Treatment Of Symptomatic Vitreomacular Adhesion (VMA)

LEUVEN, Belgium, October 18, 2012 /PRNewswire/ --

JETREA ®   is the first pharmacological agent approved for the treatment of symptomatic VMA

Conference call scheduled today at 15.00 CET (9.00 ET).

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved JETREA ® (ocriplasmin) in the USA for the treatment of symptomatic VMA, a progressive sight threatening condition. JETREA ® is the first pharmacological agent to be approved for this indication.

The recommended dose of JETREA ® is 0.125mg (0.1mL) of the diluted solution administered by intravitreal injection to the affected eye once as a single injection. JETREA ® is provided as a single use glass vial containing 0.5 mg in 0.2mL solution for intravitreal injection (2.5 mg/mL).

Dr. Patrik De Haes, CEO of ThromboGenics, said: " Today ' s FDA approval of JETREA ® is a major milestone for the Company.  We are extremely pleased that we will be able to meet a major unmet clinical need in ophthalmology when we make JETREA ® ,  the first pharmacological agent for symptomatic VMA, available to the many thousands of U.S. patients who could benefit from treatment of this progressive, sight-threatening condition. We are continuing to prepare for the planned launch of JETREA ®   in January 2013 through our own  U.S.  commercial organization. This is the biggest step in transforming ThromboGenics into a profitable biopharmaceutical company developing and commercializing innovative ophthalmic medicines. "

The approval was based on the data from ThromboGenics' Phase III program where JETREA ® was shown to be superior to placebo for the treatment of symptomatic VMA (26.5% versus 10.1%; p<0.01). Treatment with JETREA ® was associated with some, mainly transient, ocular adverse events.

Important safety and prescribing information about JETREA ® is now available at

Prof. Désiré Collen, ThromboGenics '  Chairman, said: " Just over a decade ago research with autologous plasmin suggested that JETREA ® , a proteolytic enzyme, could play an important role in the treatment of retinal disease. Since then ThromboGenics has successfully developed JETREA ® , with the support of our shareholders and a range of collaborators, resulting in today ' s  US  approval. ThromboGenics '  decision to commercialize JETREA ®   in the  US  through its own organization means that we are now in a position to maximize returns for all of our stakeholders by successfully launching this exciting innovative product. "

Dr David Boyer,  Clinical Professor of Ophthalmolo gy, affiliated with USC/Keck School of Medicine, California and leading investigator during ThromboGenics' clinical trials, stated: " JETREA ®   represents a major breakthrough for retinal specialists and their patients with symptomatic VMA. For the first time, we have a pharmacological treatment option available for many patients who would normally  only be considered surgical candidates, and that is very exciting. JETREA ®   represents a paradigm shift in clinical practice for the global retina community and a less invasive procedure for their patients."

Symptomatic VMA is a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. Market surveys conducted by ThromboGenics suggest that there are approximately 500,000 patients annually in the U.S. and the major markets of the EU who could potentially benefit from JETREA ® .

A conference call for analysts, press and investors will be hosted by Dr Patrik De Haes, CEO of ThromboGenics, and Chris Buyse, CFO of ThromboGenics, today at 15.00 CET (9.00 ET).

    The dial-in numbers and Participant Passcode for the call are set out below:
    Belgium                  0800-746-68 (Toll Free)
    France                   0805-630061 (Toll Free)
    Germany                  0800-673-7932 (Toll Free)
    Ireland                  01436-0959/ 1-800-930-488 (Toll Free)
    Netherlands              0800-022-9132 (Toll Free)
    France                   017037-7166
    UK                       +44(0)20-3003-2666/ 0808-109-0700 (Toll Free)
    USA                      1-866-966-5335 (Toll Free)
    Participant Passcode:    4871136

We request that participants dial in 5-10 minutes prior to the start time of 15:00 CET ( 09:00 ET). There will be a replay of the call available shortly after the call which will be accessible for seven days. Click here for international replay numbers followed by the Access Pin 4871136.

About  JETREA ®   ocriplasmin)

JETREA ® (ocriplasmin) is a truncated form of human plasmin that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic VMA. JETREA ® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.

JETREA ® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.

JETREA ® 's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA ® was generally well tolerated with most adverse events being transient and mild in severity.

About ThromboGenics

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs